Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Background: We retrospectively analysed relapsed/refractory MM (RRMM) patients treated with pomalidomide and dexamethasone (PomaD) either in real life, or previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015) to provide further insights o...

Full description

Bibliographic Details
Main Authors: Marina Silvia Parisi, Salvatore Leotta, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Rachele Giubbolini, Uros Markovic, Valerio Leotta, Mary Ann Di Giorgio, Daniele Tibullo, Francesco Di Raimondo, Concetta Conticello
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Journal of Clinical Medicine
Subjects:
multiple myeloma
double refractory
pomalidomide
Online Access:https://www.mdpi.com/2077-0383/8/10/1695

Internet

https://www.mdpi.com/2077-0383/8/10/1695

Similar Items